Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
The Zomedica Corp. (ZOM) news page on Stock Titan highlights company announcements, product updates, financial results, and strategic initiatives in equine and companion animal health. Zomedica describes itself as an animal health company offering point-of-care diagnostic and therapeutic device products, and its news flow reflects developments across platforms such as PulseVet, Assisi, TRUFORMA, TRUVIEW, VETGuardian, and VETIGEL.
Readers can find coverage of new product launches and enhancements, including the Assisi Loop Lounge tPEMF therapy bed, expansions of the TRUFORMA diagnostic menu such as the equine progesterone assay and feline cobalamin and folate testing, and updates on the TRUVIEW digital cytology microscope. News items also discuss the VETGuardian Zero Touch monitoring system and how it is being presented to veterinarians through educational webinars.
Zomedica’s releases frequently address distribution and market expansion, such as the expanded agreement with Grovet b.v. in the Netherlands, which broadens access to equine therapeutic devices, VETIGEL hemostatic gel, EquiLoop devices, and the TRUFORMA platform in Europe. Financial news, including quarterly results and commentary on diagnostics, therapeutic devices, consumables, and Development Services, provides insight into segment performance and the company’s stated strategy.
Investors and veterinary professionals can also follow Zomedica’s "Fourth Friday at Four" webinar series and related sessions, where the company offers strategic overviews and product-focused presentations. For anyone tracking ZOM news, this page serves as a centralized view of how Zomedica is advancing its veterinary diagnostic, monitoring, and therapeutic platforms, expanding its intellectual property portfolio, and pursuing international growth.
Zomedica Corp. (NYSE American:ZOM) reported its first quarter 2024 financial results, showcasing a 14% revenue increase to $6.3 million, with a 66% gross margin and $91 million in liquidity. The company's revenue growth was driven by both the Therapeutic Devices and Diagnostics segments, with consumable revenues reaching $4.0 million and capital revenues hitting $2.2 million. Zomedica's CEO, Larry Heaton, expressed optimism for future growth opportunities as the company continues to expand its portfolio and commercial organization.
Zomedica Corp. (NYSE American:ZOM) will be presenting at the EF Hutton Annual Global Conference on May 15, 2024. The Chief Executive Officer, Larry Heaton, will be presenting and holding investor meetings. Zomedica is a veterinary health company providing diagnostics and products for animals.
Zomedica Corp. received CE certification for its VetGuardian(R) remote contactless monitoring system, opening doors for European expansion in the $4 billion vet services market. The system utilizes radar technology for stress-free and efficient patient monitoring, enhancing operational workflow and outcomes. This milestone allows Zomedica to tap into the growing demand from veterinarians worldwide, driving innovation in the veterinary health sector.
Zomedica Corp. strengthens its market position with the issuance of three new patents for its TRUFORMA diagnostic platform. The patents cover innovative design and functionality improvements, enhancing the system's ability to detect a wide array of health conditions in horses and companion animals. With a total of 65 U.S. patents, 123 international patents, and 33 U.S. and 98 foreign trademarks, Zomedica solidifies its intellectual property portfolio and market presence in the veterinary health industry.
Zomedica Corp will report its first quarter 2024 financial results on May 9th, 2024, providing insights into its operational and financial performance. The company, focused on veterinary health products, will host a conference call and webcast to discuss the highlights of the quarter.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.